Colorectal disorders:

Indications for: ROWASA

Mild to moderate distal ulcerative colitis, proctosigmoiditis, proctitis.

Adult Dosage:

4g (60mL) daily at bedtime for 3–6 weeks. Retain enema for 8 hours.

Children Dosage:

Not established.

ROWASA Warnings/Precautions:

Sulfite sensitivity. Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. Assess renal function prior to and periodically during therapy. Discontinue if renal function deteriorates while on therapy. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers.

ROWASA Classification:


ROWASA Interactions:

Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine; consider other alternative assay.

Adverse Reactions:

Abdominal pain/cramps/discomfort, headache, flatulence, nausea, diarrhea, flu, malaise, fever, sore throat, dizziness, bloating, joint, back, or rectal pain, hemorrhoids, itching, constipation, hair loss, pancolitis, pericarditis, rash; renal impairment, acute intolerance syndrome, hypersensitivity reactions, severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP).

Drug Elimination:

Fecal, renal.

Generic Drug Availability:


How Supplied:

Enema—7, 14, 28